Comparative assessment of clinical trials, indications, pharmacokinetic parameters and side effects of approved platinum drugs

Stefka Ivanova

Abstract

Platinum complexes are among the most commonly applied anticancer agents. The aim of current work is collection, analysing and comparative estimation of clinical trials and pharmacological indications of currently approved for application platinum derivatives: Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin (Japan), Lobaplatin (China), Heptaplatin (North Korea), and Satraplatin. The other aim of the study includes the summarizing of the historic data for the stages of the development of these drugs, and the comparison of pharmacokimetic parameters, side effects and the dose-limiting factors of the drugs. The observational study on pharmacokinetic parameters shows that protein binding decreases in order: 95% (Cisplatin); 90% (Oxaliplatin); 50% (Nedaplatin); low (Carboplatin). For every of Cisplatin, Carboplatin, Oxaliplatin have been reported more than 1000 clinical trials; for Lobaplatin, Nedaplatin, Satraplatin - about 10 trials. The differences in dose-limiting effects are: neuro-, nephro-, ototoxicity (Cisplatin); neurotoxicity (Oxaliplatin); nephrotoxicity (Heptaplatin); myelosuppression: thrombocytopenia, neutropenia, leukopenia (Carboplatin, Nedaplatin, Satraplatin).

Keywords

application, Cisplatin derivatives, limiting factors

Introduction

Malignant tumors are the leading cause of lethality worldwide, and are a group of more than 100 different types of diseases, that are characterized by uncontrolled cell growth, local tissue invasion and distant metastases. The incidence of malignant tumors is enlarging, with the fastest increasing of lung, prostate, and colon cancers in men and breast carcinomas in women. Malignant tumors originate from different types of tissues: connective, epithelial, hematopoietic, lymphoid, nervous. Tumor cells are characterized by high mitotic and proliferative activity, have a shorter cell cycle duration, and a lower rate of cell death. The main difference between a normal and a tumor cell is the continuous tumor growth. Highly differentiated tumors have slower growth, metastasize relatively less frequently and later, and are less sensitive to cytostatics. Poorly differentiated cells proliferate rapidly, metastasize to distant organs, and are sensitive to cytostatics.

In carcinogenesis (oncogenesis, tumorigenesis) normal cells are transformed into cancer cells. This multistage process involves changes at the cellular and genetic levels, and involves initiation, promotion, malignant formation, progression, local tissue invasion and metastases. Initiation is
characterized with the alteration, change, or mutation of genes. Genetic alterations are result from dysregulation of biochemical signaling pathways, associated with cellular proliferation, survival, and differentiation. The actively proliferating preneoplastic cells accumulate in the promotion stage. Progression is the final stage of neoplastic transformation, and is the phase between a premalignant lesion and the development of invasive cancer. Fast increase in the tumor size, genetic and phenotypic changes, and cell proliferation occur in progression phase. Metastasis is the spread of cancer cells through the bloodstream or the lymph system, from the primary site to other parts of the body (Siddiqui et al. 2015).

The most significant risk factor for the development of cancer are genetic and environmental factors (Saeki and Sugitichi 2001) and old age (Anisimov et al. 2009). DNA damage is considered to be the primary cause of cancer. At the molecular level, tumors are considered a mutation in somatic cell DNA, caused by various carcinogenic factors. In this process, various genetic and epigenetic tumor-specific mutations occur, which define the biological features of tumor growth: uncontrolled cell proliferation, invasion of neighboring tissues and metastasis of cells to distant tissues. The main reasons for the transformation of a normal cell into a malignant one are: conversion of proto-oncogenes into oncogenes, inactivation of tumor suppressor genes (p53, RAS), and dysregulation of positive and negative signals for proliferation.

Genetic abnormalities include the following genes (Saeki and Sugitichi 2001):

I. cell cycle genes: p53 (brain and breast cancer); p16 (melanoma); Rb1 (retinoblastoma); VHL (renal cancer); WT1 (Wilms cancer)
II. DNA repair genes: BRCA1, BRCA2 (breast cancer); MLH1, MSH2, MSH6, PMS1, PMS2 (colon cancer); XPA, XBP, XPC, XPD, XPF, XPG (skin cancer)
III. signal transduction genes: MET (papillary renal cell carcinoma); NF1 (neurofibroma); RET (adrenal pheochromocytoma)
IV. genes responsible for tissue organization: APC (colon cancer); E-cadherin (gastric cancer); NF2 (neurinoma).

DNA damage can also be caused by substances, produced in the body. Macrophages and neutrophils in an inflamed colonic epithelium initiate colonic tumorigenesis (Anisimov VN et al. 2009), due to the DNA damage by reactive oxygen species. In high-fat diet, high levels of bile acids cause DNA damage, and contribute to colon cancer (Bernstein et al. 2011).

DNA damage can arise too from exposure to exogenous environmental carcinogenic agents:

I. Physical factors
   1) ionized radiation: gene mutation or chromosome aberration in lung and thyroid cancer
   2) UV-light from solar radiation: DNA damage in melanoma (Kanavy and Gerstenblith 2011)
II. Chemical factors
   1) benzo-pyrene: from tobacco smoke (Kuper et al. 2002): lung cancer, due to mutation in the p53 gene, a tumor suppressor gene, which is considered to be one of the mechanisms of carcinogenesis (Saeki et al. 2000)
   2) ethyl alcohol: esophageal cancer, due to p53 gene abnormalities (Saeki et al. 2000)
   3) cadmium: prostate cancer. (Irigaray et al. 2007)
   4) Aspergillus flavus metabolite aflatoxin: liver cancer (Smela et al. 2002)
   5) heterocyclic amines: overcooked meat and fish (de Verdier et al. 1991)

Cytotoxic chemotherapy has proven useful in a number of different cancer types including: lung, pancreatic and colorectal ca (Corrie 2008). One of the most commonly used cytostatics are platinum complexes (Wheate et al. 2010). Currently used in clinical practice: worldwide Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin (registered in Japan), Lobaplatin (approved in China), Heptaplatin (South Korea), Satraplatin - for oral administration (Ndagi et al. 2020).

In the following tables are summarized produsers (Table 1.) and names (Table 2.) of approved platinum drugs.

The development of the therapy is presented in Table 3. (Cisplatin and Carboplatin) and in Table 4. (other approved Cisplatin derivatives).

**Table 1. Manufacturers of approved platinum drugs.**

| Drug          | Producers                                                                 |
|---------------|---------------------------------------------------------------------------|
| Cisplatin     | Bristol-Myers, National Cancer Institute, Johnson Matthey and Engelhard Industries (USA) |
| Carboplatin   | Bristol-Myers Squibb, Johnson Matthey, Cancer Research Institute, Marsden Royal Hospital, London |
| Oxaliplatin   | Sanofi-Aventis, Roger Bellon Laboratories, Debiopharm Laboratories, Sanoh-Synthbalabo Laboratories |
| Nedaplatin    | Shinogi Pharmaceutical (Osaka, Japan)                                      |
| Heptaplatin   | Sunykong Industry (SK Chemicals, Kyunggi-Do)                              |
| Lobaplatin    | ASTA Medica (Germany), Zentaris AG, Haiman Tianwang (Chang’ain) International Pharmaceutical |
| Satraplatin   | Institute for Cancer Research in London and Johnson Matthey/ AnorMed       |

**Table 2. Names of approved platinum drugs.**

| Drug          | Chemica name                                   | Additional name          |
|---------------|-----------------------------------------------|--------------------------|
| Cisplatin     | cis-diamminedichloroplatinum II               | CEP35                    |
| Carboplatin   | cis-diamine-(1,1-cyclobutandecarboxylate) Pt II | Paraplatin, JM 8         |
| Oxaliplatin   | 1R,2R-diaminocyclohexane oxalate Pt II        | Elomatin                 |
| Nedaplatin    | cis-diamine-glycolate-O7, O7 Pt II            | 254-S                    |
| Lobaplatin    | cis-(trans-1,2-diaminocyclobutane-lactato) Pt II | D-19466                  |
| Heptaplatin   | cis-malonato(4R,5R)-4.5-bis (amimomethyl)-2- isopropyl-1,3-dioxo-lane) Pt II | SKID053R                 |
| Satraplatin   | bis(acetato)aminedichlorocyclohexylaminine Pt IV | JM 216                   |
Table 3. Development of the therapy with Cisplatin and Carboplatin.

| Year | Cisplatin | Carboplatin | Oxaliplatin |
|------|-----------|-------------|-------------|
| 1845 | The earliest preparation of Cisplatin by the Italian chemist Michele Peyrone. | 1988 The approval of Carboplatin by the Food and Drug Administration. | 1996 The introduction for Carboplatin in the United Kingdom. |
| 1965 | Discovering of biological activity of Cisplatin by Barnet Rosenberg. | 1979 The authorization of Platinol. | 1979 The introduction for Carboplatin in Germany. |
| 1966 | Confirmation of cis-geometry of Cisplatin by an X-ray method. | 1985 Description of various cisplatin-induced adducts formed on DNA. | 1985 Description of various cisplatin-induced adducts formed on DNA. |
| 1968 | The earliest proved activity of Cisplatin against model mice tumors. | 1987 The authorization for Carboplatin in Austria. | 1987 The authorization for Carboplatin in Austria. |
| 1970 | Cisplatin enters clinical trial in non-small cell lung cancer. | 1991 Role of elevated glutathione in inducing tumor resistance to Cisplatin. | 1991 Role of elevated glutathione in inducing tumor resistance to Cisplatin. |
| 1971 | The earliest application of Carboplatin in patients. | 1996 The generic Cisplatin Hospira receives marketing authorization. | 1996 The generic Cisplatin Hospira receives marketing authorization. |
| 1975 | The beginning of Phase II clinical trials for Cisplatin. | 1998 The introduction for Carboplatin as generic product of Teva Sante in France. | 1998 The introduction for Carboplatin as generic product of Teva Sante in France. |
| 1978 | The approval of Cisplatin by the Food and Drug Administration. | 1999 Identification of the molecular defect that causes hyperresensitivity of some testicular cancers to Cisplatin. | 1999 Identification of the molecular defect that causes hyperresensitivity of some testicular cancers to Cisplatin. |
| 1979 | The authorization of Platinol. | 1999 Identification of the molecular defect that causes hyperresensitivity of some testicular cancers to Cisplatin. | 1999 Identification of the molecular defect that causes hyperresensitivity of some testicular cancers to Cisplatin. |

Table 4. Development of the therapy with Cisplatin derivatives.

| Year | Oxa1platin (Kalayda 2020) | Carboplatin |
|------|--------------------------|-------------|
| 1996 | 1996 | Firstly approval for the second-line treatment of Oxa1platin under the trade name Eloxatin (Sanofi Aventis). |
| 1998 | 1998 | The authorization of Eloxatin for advanced colorectal cancer. |
| 1999 | 1999 | The introduction of Eloxatin in major Europe states. |
| 1992 | 1992 | The introduction of Carboplatin in Austria. |
| 2002 | 2002 | Oxa1platin FDA regulatory approval for use in the treatment of colorectal cancer. |
| 2004 | 2004 | Combination therapy: Oxaliplatin, 5-Fluorouracil and Leucovorin. |
| 1986 | 1986 | Firstly prepared by Totani et al. in Japan (Totani et al. 1986). |
| 1998 | 1998 | The approval of Nedaplatin for clinical application in Japan. |
| 2002 | 2002 | The introduction of Oxa1platin into clinical trials. |
| 2004 | 2004 | The latest application of Carboplatin in patients with small cell lung cancer. |
| 1997 | 1997 | The introduction of Carboplatin for treatment of prostate cancer. |

Cisplatin as Peyrone's chloride has been prepared by the Italian chemist Michele Peyrone. For the generic Cisplatin Hospira, the approved indication spectrum is wider than that authorised by FDA (advanced or metastatic testicular, ovarian and bladder cancer), and includes: non-small and small cell lung carcinoma, squamous cell carcinoma of the head and neck, and cervical carcinoma, when combined with chemo- or radiotherapy. In Germany Platinex has been approved on for treatment of testicular, ovarian, and bladder cancer. The indication spectrum for Carboplatin is for epithelial ovarian cancer, small cell lung carcinoma, squamous carcinoma of the head and neck, and metastatic cervical and ovarian cancer. In Austria Carboplatin indications includes: bladder cancer, squamous carcinoma of the head and neck, non-small cell lung cancer, and cervical carcinoma (Kalayda 2020).

The chemical structures of approved platinum drugs are illustrated on Table 5, and in Table 6. They are summarized in Table 7.

Cisplatin is binding to plasma proteins: gammaglobulin, albumin, transferrin, and 90% of the plasma platinum is protein-bound 2 h after 3 h infusion. Cisplatin concentrations are highest in liver, kidney, prostate; lower in muscle, pancreas, spleen, bladder, and lowest in cerebrum, cerebellum, lung, heart, adrenal. In tissues platinum is present 6 months after the last administration. The complexes between albumin and Cisplatin do not dissociate to a significant extent, and are eliminated slowly with a minimum half-life of 5 days or more.

The distribution half-life of Carboplatin is 1.1–2 h. Predominantly the drug is elimi-nated in the urine as the unchanged parent compound; 65% within 12 h, 71% within 24 h; 5% from 24 h to 96 h, without biliary elimination. The total body clearance after a 30 min. intravenous infusion of 500 mg/m² is 4.4 l/h (Reece et al. 1987). Oxa1platin plasma protein binding is primarily to albumin and gammaglobulins. The drug also irreversibly binds to erythrocytes. At the end of a 2 h infusion of Oxa1platin, 15% of the administered platinum is present in the systemic circulation, and 85% is rapidly distributed into tissues or eliminated triphasic in the urined – t ½ α = 0.43 h, t ½ β = 16.8 h, t ½ γ = 391 h (Levi et al. 2000). The excretion of Nedaplatin is renal (59.6%) (Sasaki et al. 1989; Ishibashi et al. 2003).

The indications for the approved platinum drugs are presented in Table 7.
Table 7. Indications for approved platinum drugs.

| Drug            | Indications                                                                 |
|-----------------|-----------------------------------------------------------------------------|
| Cisplatin       | ovarian (Meng et al. 2013), testicular (Dhar et al. 2011), esophagus (Kozumoi et al. 2008), stomach, colon, pancreas, liver, kidney, prostate (D'Onofrio and Madsen 2001), bladder (Dassan and Torchouw 2014), breast (Decariat et al. 2004), small cell lung, non-small cell lung (Minami et al. 2013), gastric (Kozumoi et al. 2008) cancers, malignant brain glioblastoma, head and neck squamous cell carcinoma, refractory non-Hodgkin's lymphoma and sarcoma (Dassari and Torchouw 2014), peripheral and pleural mesothelioma, neuroblastoma, metastatic melanoma, leukemia (Pavlov et al. 2006) |
| Carboplatin     | ovarian, cervical, testicular, brain, bladder, breast, head, neck and lung cancers, retinoblastoma, neuroblastoma, nephroblastoma (de Sousa et al. 2014) |
| Oxaliplatin     | ovarian, breast, head and neck cancer, non-Hodgkin's lymphoma, malignant melanoma, glioblastoma, NSCLC, neuroendocrine tumors (Spada et al. 2016) |
| Nedaplatin      | head, neck, esophagus, small cell lung, non-small cell lung cancer, ovarian, testicular, prostate, cervical cancer (Koshyama et al. 2005; Shimada et al. 2013) |
| Heptaplatin     | gastric (Hong et al. 1996), small cell lung cancer (Hong et al. 1995; Zang et al. 1999) |
| Lobaplatin      | chronic myelogenous leukemia, small-cell lung, breast, gastric cancer, esophagel squamous cell and hypopharyngeal carcinoma, osteosarcoma (Giese et al. 1993; Drgin et al. 1995; Wu et al. 2018) |
| Satraplatin     | lung, breast, cervical, prostate and ovarian cancer (Bhargava and Vaishampayan 2009) |

Table 8. Clinical trials for Cisplatin, Carboplatin, Lobaplatin.

The data for the clinical trials are shown on Table 8. (Cisplatin, Carboplatin, Lobaplatin) and on Table 9. (Oxaliplatin, Nedaplatin, Satraplatin).

Neurotoxicity is the most important adverse effect of Cisplatin chemotherapy in 47% of patients. Symptoms include numbness, tingling, paraesthesia in the limbs, difficulty walking, decreased sensation of tendon reflexes. Neuropathy is long-term with significant worsening of symptoms during the first 4 months, which may continue 52 months after stopping treatment. Higher concentrations in peripheral nervous system tissues (peripheral nerves and dorsal root ganglia), compared to central nervous system tissues (brain, spinal cord) correlate with clinical symptoms of peripheral neuropathy.

Toxicity of platinum compounds is presented on Table 10 (Hartmann and Lipp 2003).

Recent developments in antitumor coordination compounds (Momekov et al. 2005) as hematoporphyrin IX complexes: monomeric platinum (III) (Momekov et al. 2010), paramagnetic platinum (Gencheva et al. 2007), palladium III (Momekov et al. 2018), and gold II complexes (Momekov et al. 2018), as hematoporphyrin IX complexes: monomeric platinum (III) (Momekov et al. 2018), paramagnetic platinum (Gencheva et al. 2007), palladium III (Momekov et al. 2018), and gold II complexes (Momekov et al. 2005); platinum (IV) agents: Enthacraplatin, Mitaplatin, Ormaplatin (Tetraplatin), Satraplatin (Monneret 2011).
Conclussion

More than 1000 clinical trials have been reported for every of the following anticancer agents: Cisplatin, Carboplatin, Oxaliplatin. The more investigations have been applied for Cisplatin. In comparison, for Lobaplatin, Nedlyaplatin, and Satraplatin have been reported very few clinical trials – about 10 for every drug. The following differences in dose-limiting effects have been reported: neuro-, nephro-, and ototoxicity (Cisplatin); neurotoxicity (Oxaliplatin); nephrotoxicity (Heptaplatin); myelosuppression: thrombocytopenia, neutropenia and leukopenia (Carboplatin, Nedaplatin, Satraplatin).

Conflict of interests

There are no conflict of interests.

References

Ahn JH, Kang YK, Kim TW, Bahng H, Chang HM, Kang WC, Kim WK, Lee JS, Park JS (2002) Nephrotoxicity of Heptaplatin: a randomized comparison with Cisplatin in advanced gastric cancer. Cancer Chemotherapy and Pharmacology 50(2): 104–110. https://doi.org/10.1007/s00280-002-0483-x
Anisimov VN, Sikora E, Pawelec G (2009) Relationships between cancer and aging: a multilevel approach. Biogerontology 10(4): 323–338. https://doi.org/10.1007/s10522-008-9209-8
Argyriou AA, Polychronopoulos P, Iaconomou G, Chroni E, Kalofonos HP (2008) A review on Oxaliplatin-induced peripheral nerve damage. Cancer Treatment Reviews 34(4): 368–377. https://doi.org/10.1016/j.ctrv.2008.01.003
Avan A, Postma TJ, Ceresa C, Avan A, Cavaletti G, Giovannetti E, Peters GI (2015) Platinum-induced neurotoxicity and preventive strategies: past, present, and future. The Oncologist 20(4): 411–432. https://doi.org/10.1634/theoncologist.2014-0044
Bernstein C, Holubec H, Bhatchariya AK, Nguyen H, Payne CM, Zaitlin B (2011) Bernstein H. Carcinogenicity of deoxycholate, a secondary bile acid. Archives of Toxicology 85(8): 863–871. https://doi.org/10.1007/s00204-011-0648-7
Bhargava A, Vaishampayan UN (2009) Satraplatin: leading the new generation of oral platinum agents. Expert Opinion on Investigational Drugs 18(11): 1787–1797. https://doi.org/10.1517/13543780903362437
Cassidy J, Misset JL (2002) Oxaliplatin-related side effects: characteristics and management. Seminars in Oncology 29(5)(Suppl 15): 11–20. https://doi.org/10.1053/sonc.2002.35524
Chay WY, Chew L, Yeoh TT, Tan MH (2010) An association between transient hypokalemia and severe acute Oxaliplatin-related toxicity predominantly in women. Acta Oncologica 49(5): 515–517. https://doi.org/10.3109/02841860903646015
Chung MK, Kim JC, Roh JK (1988) Embryotoxic effects of SKI 2053R, a new potential anticancer agent, in rats. Reproductive Toxicology 36(1): 375–381. https://doi.org/10.1016/s0899-6238(98)00016-1
Corrge GP (2008) Cytoxic chemotherapy: clinical aspects. Medicine 36(1): 24–28. https://doi.org/10.1016/j.mpmed.2007.10.012
Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. European Journal of Pharmacology 740(1): 364–378. https://doi.org/10.1016/j.ejphar.2014.07.025
de Sousa GF, Wlodarczyk RS, Montei G (2014) Carboplatin: molecular mechanisms of action associated with chemoresistance Brazilian Journal of Pharmaceutical Sciences 50(4): 693–700. https://doi.org/10.1590/S1984-82502014000400004
de Verdier MG, de Sousa GF, Wlodarczyk RS, Montei G (2014) Carboplatin: molecular mechanisms of action associated with chemoresi-
tance Brazilian Journal of Pharmaceutical Sciences 50(4): 693–700. https://doi.org/10.1590/S1984-82502014000400004
Decatris MP, Sundar S, O’Byrne KJ (2004) Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treatment Reviews 30(1): 53–81. https://doi.org/10.1016/S0305-7372(03)00139-7
Degardin M, Armand JP, Chevallier B, Cappelaere P, Lentz MA, David M, Roché H (1995) A clinical screening cooperative group phase II evaluation of Lobaplatin (ASTA D-19466) in advanced head and neck cancer. Investigational New Drugs 13(3): 253–255. https://doi.org/10.1007/BF00873809
Desoıze B, Madoulet C (2002) Particular aspects of platinum compounds used at present in cancer treatment. Critical Reviews in Oncology/Hematology 42(3): 317–325. https://doi.org/10.1016/s1040-8428(01)00219-0
Dhar S, KoliShtetti N, Lippard SJ, Farokhzad OC (2011) Targeted delivery of a Cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proceedings of the National Academy of Sciences of the United States of America 108(5): 1850–1855. https://doi.org/10.1073/pnas.111379108
Doneva N, Borsev N, Gencheva G, Tsekov D, Momekov G (2014) Onkoparmacological evaluation of cytotoxic platinum, palladium and gold metal complexes with porphyrin ligands, 115(1): 313–313.
Gebremedhin EG, Shorland PJ, Mahns DA (2018) The incidence of acute Oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review. BMC Cancer 18(1): 410–410. https://doi.org/10.1186/s12885-018-4185-0
Gencheva G, Tsekov D, Gochev M, Momekov G, Tyuliev G, Skumryev V, Karaivanova M, Bontchev PR (2007) Synthesis, structural characterization and cytotoxic activity of novel paramagnetic platinum hematoporphyrin IX complexes – potent antitumour agents, Metal-Based Drugs 2007(1): 1–13. [67376]. https://doi.org/10.1155/2007/67376
Gienema, JA, de Vries EG, Sleijfer DT, Willems PH, Guchelaar HJ, Uges DR, Aulenbacher P, Voegeli R, Mulder NH (1993) A phase I study of 1,2-diaminomethylcyclobutane-platinum(II)-lactate (D-19466; Lobaplatin) administered daily for 5 days. British Journal of Cancer 67(2): 396–401. https://doi.org/10.1038/bjc.1993.73
Hagman U, Peters RK, Steineck G, Overvik E (1991) Meat, cooking and aging: a multilevel approach. Biogerontol 10(4): 323–338. https://doi.org/10.1007/s00280-002-0483-x
Handa O, Naito Y, Yoshikawa T (2011) Redox biology and gastric carcinogenesis: the role of Helicobacter pylori. Redox Rep. 16(1): 1–7. https://doi.org/10.1179/174329211X12968219310756
Ivanova S: Comparative assessment of approved platinum drugs

Hartmann JT, Lipp HP (2003) Toxicity of platinum compounds. Expert Opinion on Pharmacotherapy 4(6): 889–901. https://doi.org/10.1517/14646556.4.6.889

Hong WS, Kim HT, Kim KH, Kim DK (1995) In vitro antitumor activity of a new platinum complex, cismalonato ((4R,SR)-4,5-bis(ami-nomethyl)-2-isopropyl-1,3-dioxolane) platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines. Anticancer Res 15(1): 51–54. [PMID: 77336402]
https://go.drugbank.com/drugs/DB00515
https://go.drugbank.com/drugs/DB00958
https://go.drugbank.com/drugs/DB13049
https://go.drugbank.com/drugs/DB00526
https://go.drugbank.com/drugs/DB13145
https://go.drugbank.com/drugs/DB04996S

Ishibashi T, Yano Y, Oguma T (2003) Population pharmacokinetics of platinum after Nedaplatin administration and model validation in adult patients. British Journal of Clinical Pharmacology 56(2): 205–213. https://doi.org/10.1046/j.1365-2125.2003.01871.x

Isgaray P, Newby JA, Clapp R, Hardell L, Howard V, Montagnier L, Epstein S, Belpomme D (2007) Lifestyle-related factors and environmental agents causing cancer: an overview. Biomedicine & Pharmacotherapy 61(10): 640–658. https://doi.org/10.1016/j.biopha.2007.10.006

Kalayda GSG (2020) History of platinum-based drugs from a regulatory perspective. Thesis for Master of Drug Regulatory Affairs, Bonn.

Kanavy HE, Gerstenblith MR (2011) Ultraviolet radiation and melanoma. Seminars in Cutaneous Medicine and Surgery 30(4): 222–228. https://doi.org/10.1016/s1063-7227(11)70003-4

Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Miyauchi H, Sugiuchi K, Shibata H, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagai T, Takeuchi M (2008) S-1 plus Cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. The Lancet Oncology 9(3): 215–221. https://doi.org/10.1016/S1470-2045(08)70035-4

Koshiyama M, Kinezaki M, Uchida T, Sumitomo M (2005) Chemosensitivity testing of a novel platinum analog, Nedaplatin (254-S) in human gynecological carcinomas: a comparison with cisplatin. Anti-cancer Research 25(6C): 4499–4502. [PMID: 16334133]

Kuper H, Boffetta P, Adami HO (2002) Tobacco use and cancer causation: association by tumour type. Journal of Internal Medicine 252(3): 206–224. https://doi.org/10.1046/j.1365-2976.2002.01022.x

Levi F, Metzger G, Massari C, Milano G. Oxaliplatin: pharmacokinetic and pharmacological aspects. Clinical Pharmacokinetics 2000, 38(1): 1–21. https://doi.org/10.2165/00003088-200038010-00001

Markman M (2003) Toxicities of the platinum antineoplastic agents. Expert Opinion on Drug Safety 2(6): 597–607. https://doi.org/10.1517/14740338.2.6.597

Meng F, Sun G, Zhong M, Yu Y, Brewer MA (2013) Anticancer efficacy of Cisplatin and Trichostatin A or 5-aza-20-deoxycytidine on ovarian cancer. British Journal of Cancer. 108(3): 579–586. https://doi.org/10.1038/bjc.2013.10

Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2(11): 2490–2518. https://doi.org/10.3390/toxins2112490

Minami D, Takigawa N, Takada H, Takata M, Ochi N, Ichihara E, Hisamoto A, Hotta K, Tanimoto M, Kiura K (2013) Synergistic effect of Olaparib with combination of Cisplatin on PTEN-deficient lung cancer cells. Molecular Cancer Research 11(2): 140–148. https://doi.org/10.1158/1541-7786.MCR-12-0401

Momokov G, Momokova D (2006) Recent developments in antitumor platinum coordination compounds. Expert Opinion on Therapeutic Patents 16(90): 1383–1403. https://doi.org/10.1517/13543776.16.10.1383

Momokov G, Bakalova A, Kariaivanova M (2005) Novel approaches towards development of non-classical platinum-based antineoplastic agents: design of platinum complexes characterized by an alternative DNA-binding pattern and/or tumor-targeted cytototoxicity. Current Medicinal Chemistry 12(19): 2177–2191. https://doi.org/10.2174/092986705754864877

Momokov G, Ugrinova I, Pashева E, Tseková D, Gencheva G (2018) Cellular pharmacology of palladium (III) hematoporphyrin IX complexes: solution stability, antineoplastic and apoptogenic activity, DNA binding, and processing of DNA-adducts. International Journal of Molecular Sciences 19(3): 1–21. https://doi.org/10.3390/ijms19082451

Momokov G, Ferdinandov D, Konstantinov S, Arpadjan S, Tseková D, Gencheva G, Bontchev PR, Kariaivanova M (2008) In vitro evaluation of a stable monomeric gold (II) complex with hematoporphyrin IX: cytotoxicity against tumor kidney cells, cellular accumulation and induction of apoptosis. Bioorganic Chemistry and Applications 2008(1): 1–8. [367471] https://doi.org/10.1155/2008/367471

Momokov G, Kariaivanova M, Ugrinova I, Pashева E, Gencheva G, Tseková D, Arpadjan S, Bontchev P (2010) In vitro pharmacological study of monomeric platinum (III) hematoporphyrin IX complexes. Investigational New Drugs 29(5): 742–751. https://doi.org/10.1007/s10637-010-9412-8

Monneret C (2011) Platinum anticancer drugs. From serendipity to rational design. Annales Pharmaceutiques Françaises 69(6): 286–295. https://doi.org/10.1016/j.pharma.2011.10.001

Ndagi U, Mlhongo N, Soliman ME (2017) Metal complexes in cancer therapy – an update from drug design perspective. Drug Design, Development and Therapy 11(1): 599–616. https://doi.org/10.2147/DDDT.S119488

Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K, Smyth RD (1988) Clinical pharmacokinetics of Carboplatin. Journal of Clinical Pharmacology 28(3): 208–215. https://doi.org/10.1002/j.1552–4604.1988.tb03134.x

Oun R, Moussa YE, Wheate NJ (2018) The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Transactions journal 47(19): 6645–6653. https://doi.org/10.1039/c8dt00838h

Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney International 73(9): 994–1007. https://doi.org/10.1038/sj.ki.5002786

Previati M, Lanzoni I, Corbacella E, Magosso S, Guaran V, Martini A, Captiani (2006) Cisplatin-induced apoptosis in human promyelocytic cells. International Journal of Molecular Medicine 18(3): 511–516. https://doi.org/10.2174/0929867058003134x

Rice RA, Bishop JE, Oliver IN, Stafford I, Hillcoat BL, Morstyn G (1987) Pharmacokinetics of unchanged Carboplatin (CBDDA) in patients with small cell lung carcinoma. Cancer Chemotherapy and Pharmacology 19(4): 326–330. https://doi.org/10.1007/BF00261482

Saeki H, Sugichishi K (2001) Carcinogenic risk factors. [MJ] 44(6): 245–249.

Saeki H, Ohno S, Araki K, Egashira A, Kawaguchi H, Ikeda Y, Morita M, Kitamura K, Sugimachi K (2000) Alcohol consumption and cigarette smoking in relation to high frequency of p53 protein accumulation
in oesophageal squamous cell carcinoma in the Japanese. British Journal of Cancer 82(11): 1892–1894. https://doi.org/10.1038/bjoc.1999.1212

Samaras V, Rafailidis PI, Mourtzoukou EG, Peppas G, Falagas ME (2010) Chronic bacterial and parasitic infections and cancer: a review. Journal of Infection in Developing Countries 4(5): 267–281. https://doi.org/10.3855/jidc.819

Sasaki Y, Tamura T, Eguchi K, Shinakai T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S, Koichi Minato K, Nakagawa K (1989) Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with Cisplatin and Carboplatin. Cancer Chemotherapy and Pharmacology 23(4): 243–246. https://doi.org/10.1007/BF00451649

Shaili E (2014) Platinum anticancer drugs and photochemotherapeutic agents: recent advances and future developments. Science Progress 97(1): 20–40. https://doi.org/10.3184/003685014X13904811808460

Shimada, M, Itamochi H, Kigawa J (2013) Nedaplatin: a cisplatin derivative in cancer chemotherapy. Cancer Management and Research 5(1): 67–76. https://doi.org/10.2147/CMAR.S335785

Siddiqui IA, Sanna V, Ahmad N, Sechi M, Mukhtar H (2015) Resveratrol nanoformulation for cancer prevention and therapy. Annals of the New York Academy of Sciences 1348(1): 20–31. https://doi.org/10.1111/nyas.12811

Smela ME, Hamm ML, Henderson PT, Harris CM, Harris TM, Essigmann JM (2002) The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America 99(10): 6655–6660. https://doi.org/10.1073/pnas.102167699

Sooriyarachchi M, Narendran A, Guiler J (2011) Comparative hydrolysis and plasma protein binding of Cisplatin and Carboplatin in human plasma in vitro. Metallomics 3(1): 49–55. https://doi.org/10.1039/c0mt00058b

Spada F, Antonuzzo L, Marconcini R, Radice D, Antonuzzo A, Ricci S, Di Costanzo, Fontana A, Gelsomino F, Luppi G, Nobili E, Galdy S, Cell A, Sonzogni A, Pisa E, Barberis M, Fazio N (2016) Oxaliplatin-based chemotherapy in advanced neuroendocrine tumors: clinical outcomes and preliminary correlation with biological factors. Neuroendocrinol 103(6): 806–814. https://doi.org/10.1159/000444087

Totani T, Aono K, Komura M, Adachi Y (1986) Synthesis of (glycolato-O,O') diammineplatinum (II) and it's related complexes. Chemistry Letters 15(3): 429–432. https://doi.org/10.1246/cl.1986.429

Waissbluth S, Daniel SJ (2013) Cisplatin-induced ototoxicity: transporters playing a role in Cisplatin toxicity. Hearing Research 299(1): 37–45. https://doi.org/10.1016/j.heares.2013.02.002

Wheate NJ, Walker S, Craig GE, Oun R (2010) The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 39(35): 8113–8127. https://doi.org/10.1039/c0dt00292e

Wu X, Tang P, Li S, Wang S, Liang Y, Zhong L, Ren L, Zhang T and Zhang Y (2018) A randomized and open-label phase II trial reports the efficacy of neoadjuvant Lobaplatin in breast cancer. Nature Communications 9(1): 1–8. [832] https://doi.org/10.1038/s41467-018-03210-2

Yao X, Panichpiskal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. The American Journal of the Medical Sciences 334(2): 115–124. https://doi.org/10.1097/MAJ.0b013e318121df1e

Zang DY, Lee KH, Lee JS, Lee JH, Kim WK, Kim SH, Kim WD, Kim DS, Kim JH, Kim BS, Cho YB, Kim DK, Kim KH (1999) Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small-cell lung cancer. American Journal of Clinical Oncology 22(5): 495–498. https://doi.org/10.1097/00000421-199910000-00015